Immunometabolism In Brain Aging and Neurodegeneration: Bridging Metabolic Pathways and Immune Responses DOI Creative Commons

Shokofeh Rahimpour,

Briana L Clary, Sanaz Nasoohi

et al.

Aging and Disease, Journal Year: 2024, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2024

The complex set of interactions between the immune system and metabolism, known as immunometabolism, has emerged a critical regulator disease outcomes in central nervous system. Numerous studies have linked metabolic disturbances to impaired responses brain aging, neurodegenerative disorders, injury. In this review, we will discuss how disruptions immunometabolism balance contribute pathophysiology dysfunction. first part review summarizes contributions cell populations such microglia, astrocytes, infiltrating cells mediating inflammation metabolism CNS disorders. remainder addresses impact changes on activation progression Alzheimer's disease, Parkinson's multiple sclerosis, stroke, spinal cord injury, traumatic Furthermore, also address therapeutic potential targeting immunometabolic pathways reduce neuroinflammation slow progression. By focusing among mechanisms they recruit present comprehensive overview human health disease.

Language: Английский

Beneficial Effects of Human Schwann Cell-Derived Exosomes in Mitigating Secondary Damage After Penetrating Ballistic-Like Brain Injury DOI
Kengo Nishimura,

Juliana Sanchez‐Molano,

Nadine Kerr

et al.

Journal of Neurotrauma, Journal Year: 2024, Volume and Issue: 41(21-22), P. 2395 - 2412

Published: March 6, 2024

There is a growing body of evidence that the delivery cell-derived exosomes normally involved in intracellular communication can reduce secondary injury mechanisms after brain and spinal cord improve outcomes. Exosomes are nanometer-sized vesicles released by Schwann cells may have neuroprotective effects reducing posttraumatic inflammatory processes as well promoting tissue healing functional recovery. The purpose this study was to evaluate beneficial human Schwann-cell (hSC-Exos) severe model penetrating ballistic-like (PBBI) rats investigate on multiple Human cell processing protocols followed Current Good Manufacturing Practices (cGMP) with exosome extraction purification steps approved FDA for an expanded access single ALS patient IND. Anesthetized male Sprague-Dawley (280-350g) underwent PBBI surgery or sham procedures starting 30 min received either dose hSC-Exos PBS through jugular vein. At 48hrs PBBI, flow cytometry analysis cortical revealed administration reduced number activated microglia levels caspase-1, marker inflammasome activation. Neuropathological at 21 days showed treatment significantly overall contusion volume decreased frequency Iba-1 positive amoeboid immunocytochemical analysis. This systemic TBI reduces histopathological damage. represents clinically relevant cell-based therapy limit detrimental neurotrauma other progressive neurological injuries impacting pathophysiological events

Language: Английский

Citations

5
Inhibition of TREM-1 alleviates neuroinflammation by modulating microglial polarization via SYK/p38MAPK signaling pathway after traumatic brain injury DOI

Tianqi Zhao,

Yuxin Zhou, Dabing Zhang

et al.

Brain Research, Journal Year: 2024, Volume and Issue: 1834, P. 148907 - 148907

Published: April 1, 2024

Language: Английский

Citations

5
Mailuo Shutong pills inhibit neuroinflammation by regulating glucose metabolism disorders to protect mice from cerebral ischemia-reperfusion injury DOI

Yongxia Guan,

Lihong Pan,

Dejun Niu

et al.

Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 335, P. 118621 - 118621

Published: July 24, 2024

Language: Английский

Citations

5
Crosstalk between macrophages and immunometabolism and their potential roles in tissue repair and regeneration DOI Creative Commons
Hongbo Ma, Limei Gao, Rong Chang

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(18), P. e38018 - e38018

Published: Sept. 1, 2024

Language: Английский

Citations

5
MRI‐T2 Relaxometry is Increased in Mild Traumatic Brain Injury: Indications of Acute Brain Abnormalities After Injury DOI Creative Commons
Mayan J. Bedggood, C. Essex, Alice Theadom

et al.

Journal of Neuroscience Research, Journal Year: 2025, Volume and Issue: 103(4)

Published: April 1, 2025

Mild traumatic brain injury (mTBI) is a common condition, particularly pervasive in contact sports environments. A range of symptoms can accompany this type and negatively impact people's lives. As mTBI diagnosis recovery largely rely on subjective reports, more objective markers are needed. The current study compared structural MRI-T2 relaxometry between group 40 male athletes with within 14 days age-matched controls. Voxel-averaged T2 the gray matter was increased for to controls (p < 0.001), statistically significant superior cortical regions. Our findings indicate subtle abnormalities be identified acute using relaxometry. These may reflect inflammation present could constitute an marker supplement methods that dominate clinical decisions regarding prognosis. Future research should validate potential other data types, such as blood biomarkers or histological samples.

Language: Английский

Citations

0
Immunity in neuromodulation: probing neural and immune pathways in brain disorders DOI Creative Commons

Camille M. Hours,

Pia Vayssière,

Pierre Gressèns

et al.

Journal of Neuroinflammation, Journal Year: 2025, Volume and Issue: 22(1)

Published: April 28, 2025

Immunity finely regulates brain function. It is directly involved in the pathological processes of neurodegenerative diseases such as Parkinson's and Alzheimer's disease, post-stroke conditions, multiple sclerosis, traumatic injury, psychiatric disorders (mood disorders, major depressive disorder (MDD), anxiety psychosis schizophrenia, neurodevelopmental (NDD)). Neuromodulation currently a leading therapeutic strategy for treatment these but little yet known about its immune impact on neuronal function precise beneficial or harmful consequences. We review relevant clinical preclinical studies identify several specific modifications. These data not only provide insights into how neuromodulation acts to optimize immune-brain interactions, also pave way better understanding interactions processes.

Language: Английский

Citations

0
The potential of repurposing clemastine to promote remyelination DOI Creative Commons
Reiji Yamazaki, Nobuhiko Ohno

Frontiers in Cellular Neuroscience, Journal Year: 2025, Volume and Issue: 19

Published: May 7, 2025

White matter in the central nervous system comprises bundled nerve fibers myelinated by oligodendrocytes. injury, characterized loss of oligodendrocytes and myelin, is common after ischemic brain inflammatory demyelinating diseases including multiple sclerosis, traumatic damage such as spinal cord injury. Currently, no therapies have been confirmed to promote remyelination these diseases. Over past decade, various reports suggested that anti-muscarinic drug clemastine can stimulate Consequently, repurposing a potential treatment for variety neurological disorders has gained significant attention. The therapeutic effects demonstrated animal models, its mechanisms action are currently being investigated. In this review, we summarize relating administration white injury disease discuss promotion.

Language: Английский

Citations

0
Astrocytes at the intersection of ageing, obesity, and neurodegeneration DOI
Wyn Firth, Katherine R. Pye, Paul G. Weightman Potter

et al.

Clinical Science, Journal Year: 2024, Volume and Issue: 138(8), P. 515 - 536

Published: April 1, 2024

Abstract Once considered passive cells of the central nervous system (CNS), glia are now known to actively maintain CNS parenchyma; in recent years, evidence for glial functions physiology and pathophysiology has only grown. Astrocytes, a heterogeneous group cells, play key roles regulating metabolic inflammatory landscape have emerged as potential therapeutic targets variety disorders. This review will outline astrocyte healthy ageing, obesity, neurodegeneration, with focus on responses mitochondrial function, address outlooks.

Language: Английский

Citations

2
Mitochondrial-targeted therapies in traumatic brain injury: From bench to bedside DOI Creative Commons
Sidra Tabassum,

Silin Wu,

Chang‐Hun Lee

et al.

Neurotherapeutics, Journal Year: 2024, Volume and Issue: unknown, P. e00515 - e00515

Published: Dec. 1, 2024

Traumatic brain injury (TBI) is a leading cause of morbidity and mortality worldwide, with limited effective therapeutic options currently available. Recent research has highlighted the pivotal role mitochondrial dysfunction in pathophysiology TBI, making mitochondria an attractive target for intervention. This review comprehensively examines advancements mitochondrial-targeted therapies bridging gap from basic to clinical applications. We discuss underlying mechanisms damage including oxidative stress, impaired bioenergetics, dynamics, apoptotic pathways. Furthermore, we highlight complex interplay between dysfunction, inflammation, blood-brain barrier (BBB) integrity, elucidating how these interactions exacerbate impede recovery. also evaluate various preclinical studies exploring pharmacological agents, gene therapy, novel drug delivery systems designed protect restore function. Clinical trials their outcomes are assessed translational potential TBI. By integrating findings bench bedside, this emphasizes promising avenues addresses remaining challenges. It provides guidance future pave way innovative treatments that improve patient

Language: Английский

Citations

2
High-dimensional proteomic analysis for pathophysiological classification of Traumatic Brain Injury DOI
Lucia M. Li, Eleftheria Kodosaki,

Amanda Heselgrave

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 28, 2024

Abstract Pathophysiology and outcomes after Traumatic Brain Injury (TBI) are complex highly heterogenous. Current classifications uninformative about pathophysiology, which limits prognostication treatment. Fluid-based biomarkers can identify pathways proteins relevant to TBI pathophysiology. Proteomic approaches well suited exploring mechanisms of disease, as they enable sensitive assessment an expansive range proteins. We used novel high-dimensional, multiplex proteomic assays study changes in plasma protein expression acute moderate-severe TBI. analysed samples from 88 participants the longitudinal BIO-AX-TBI cohort (n=38 within 10 days injury, n=22 non-TBI trauma, n=28 non-injured controls) on two platforms: Alamar NULISA™ CNS Diseases OLINK ® Target 96 Inflammation. Participants also had data available Simoa (neurofilament light, GFAP, total tau, UCHL1) Millipore (S100B). The panel assesses 120 proteins, most have not been investigated before TBI, such differentiate trauma controls. A subset (n=29 n=24 subacute 3T MRI measures lesion volume white matter injury (fractional anisotropy, scanned 6 weeks injury). Differential Expression analysis identified 16 with TBI-specific significantly different expression. These were neuronal markers (calbindin2, UCHL1, visinin-like protein1), astroglial (S100B, GFAP), tau other neurodegenerative disease (total pTau231, PSEN1, amyloid beta42, 14-3-3γ), inflammatory cytokines (IL16, CCL2, ficolin2), cell signalling (SFRP1), metabolism (MDH1) autophagy related (sequestome1) Acute levels pTau231 correlated volume, while sequestome1 was whole skeleton fractional anisotropy CCL2 inversely corpus callosum FA. Neuronal, astroglial, each other, IL16, MDH1 sequestome1. Clustering ( k means) by 3 subgroups differential patterns, but did differ age or outcome. Proteins that overlapped platforms excellent r >0.8) correlations between values. involved processing, cellular processes autophagy. patterns thus demonstrating previously only studied animal models human Our highlights potential improve classification understanding implications for treatment development.

Language: Английский

Citations

1